Advertisement

Clinical Use of Opioids

  • Andrea Trescot
Chapter

Abstract

Opioids are compounds that work at specific receptors in the brain to provide analgesia. Originally extracted from the sap of the poppy plant, opioids may be naturally occurring, semisynthetic, or synthetic, and their clinical activity is a function of their affinity for the opioid receptors in the brain. Opioids are useful for a wide variety of painful conditions, including acute pain, cancer pain, and chronic pain, as well as cough suppression and air hunger. However, opioid use is associated with a significant risk of addiction potential, which limits their use and contributes to the current “opioid phobia.” In this chapter, we will discuss the history, pharmacology, clinical uses, and future directions.

Keywords

Opioid Receptor Cancer Pain Postherpetic Neuralgia Central Sleep Apnea Oral Morphine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Breasted JG. Ancient records of Egypt. University of Chicago Oriental Institute Publications, vol. III. Chicago: University of Chicago Press; 1930. p. 217.Google Scholar
  2. 2.
    Schwarz S, Huxtable R. The isolation of morphine. Mol Interv. 2001;1(4):189–91.PubMedGoogle Scholar
  3. 3.
    The role of chemistry in history. 2010. http://itech.dickinson.edu/chemistry/?cat=107. Accessed 15 Mar 2010.
  4. 4.
    Jurna I. Serturner and morphine – a historical vignette. Schmerz. 2003;17(4):280–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Trescot A, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(opioid special issue):S133–53.PubMedGoogle Scholar
  6. 6.
    Pert CB, Snyder SH. Opiate receptor: its demonstration in nervous tissue. Science. 1973;179:1011–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Hughes J, Smith T, Kosterlitz H, Fothergill L, Morgan B, Morris H. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975;258:577–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Fukuda K. Intravenous opioid anesthetics. In: Miller RD, editor. Miller’s anesthesia. 6th ed. Philadelphia: Elsevier; 2005.Google Scholar
  9. 9.
    Chahl LA. Opioids – mechanism of action. Aust Prescr. 1996;19:63–5.Google Scholar
  10. 10.
    Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci. 2001;2:119–28.PubMedCrossRefGoogle Scholar
  11. 11.
    Fillingim RB, Kaplan L, Staud R, et al. The A118G single nucleotide polymorphism of the μ-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain. 2005;6(3):159–67.PubMedCrossRefGoogle Scholar
  12. 12.
    Smith HS. Variations in opioid responsiveness. Pain Physician. 2008;11:237–48.PubMedGoogle Scholar
  13. 13.
    Klepstad P, Kaasa S, Skauge M, Borchgrevink PC. Pain intensity and side effects during titration of morphine in cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand. 2000;44(6):656–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Bertilsson L, Dahl ML, Ekqvist B, Jerling M, Lierena A. Genetic regulation of the disposition of psychotropic drugs. In: Meltzer HY, Nerozzi D, editors. Current practices and future developments in the pharmacotherapy of mental disorders. Amsterdam: Elsevier; 1991. p. 73–80.Google Scholar
  15. 15.
    Stamer UM, Stuber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol. 2007;20(5):478–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54(5):463–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(opioid special issue):S105–20.PubMedGoogle Scholar
  18. 18.
    McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–56.PubMedGoogle Scholar
  19. 19.
    Swegle JM, Logemann C. Opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–52.PubMedGoogle Scholar
  20. 20.
    Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain Med. 2001;93:247–57.CrossRefGoogle Scholar
  21. 21.
    Flake ZA, Scalley RG, Bailey AG. Practical selection of antiemetics. Am Fam Physician. 2004;69:1169–74.PubMedGoogle Scholar
  22. 22.
    Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542–54.PubMedGoogle Scholar
  23. 23.
    Cherny NI. The management of cancer pain. CA Cancer J Clin. 2000;50:70–116.PubMedCrossRefGoogle Scholar
  24. 24.
    Teichtahl H, Prodromidis A, Miller B, et al. Sleep-disordered breathing in stable methadone programme patients: a pilot study. Addiction. 2001;96(3):395–403.PubMedCrossRefGoogle Scholar
  25. 25.
    Downey R, Gold PM. Obstructive sleep apnea. 2010. http://emedicine.medscape.com/article/295807-print. Accessed Apr 2010.
  26. 26.
    Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest. 2005;128(3):1348–56.PubMedCrossRefGoogle Scholar
  27. 27.
    Howlett TA, Rees LH. Endogenous opioid peptides and hypothalamopituitary function. Annu Rev Physiol. 1986;48:527–36.PubMedCrossRefGoogle Scholar
  28. 28.
    Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36.PubMedGoogle Scholar
  29. 29.
    Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Merza Z. Chronic use of opioids and the endocrine system. Horm Metab Res. 2010;42(9):621–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res. 1996;21(11):1375–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Zacny JP. Morphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol Depend. 2001;63:23–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Zun LS, Downey LV, Gossman W, Rosenbaumdagger J, Sussman G. Gender differences in narcotic-induced emesis in the ED. Am J Emerg Med. 2002;20(3):151–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Cepeda MS, Farrar JT, Roa JH, et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2001;70(4):351–61.PubMedGoogle Scholar
  35. 35.
    Lotsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet. 2001;40:485–99.PubMedCrossRefGoogle Scholar
  36. 36.
    Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27:524–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Wasan AD, Michna E, Janfaza D, Greenfield S, Teter CJ, Jamison RN. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med. 2008;9:918–23.PubMedCrossRefGoogle Scholar
  38. 38.
    MedWatch safety labeling change. 2010. www.fda.gov/medwatch/safety/2007/safety07.htm#Codeine. Accessed Jan 2010.
  39. 39.
    Rodriguez RF, Castillo JM, del Pilar Castillo M, et al. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study. Clin Ther. 2007;29(4):581–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33:617–21.PubMedCrossRefGoogle Scholar
  41. 41.
    Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag. 2008;4(3):131–44.PubMedGoogle Scholar
  42. 42.
    Foley KM, Abernathy A. Management of cancer pain. In: Devita VT, Lawrence TS, Rosenberg SA, editors. Devita, Hellman & Rosenberg’s cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.Google Scholar
  43. 43.
    Murray A, Hagen NA. Hydrocodone. J Pain Symptom Manage. 2005;29:S57–66.PubMedCrossRefGoogle Scholar
  44. 44.
    Vallner JJ, Stewart J, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981;214:152–6.Google Scholar
  45. 45.
    Davis MP, McPherson ML. Tabling hydromorphone: do we have it right? J Palliat Med. 2010;13(4):365–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001;69(4):409–20.PubMedCrossRefGoogle Scholar
  47. 47.
    Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manag. 2005;10:133–44.PubMedGoogle Scholar
  48. 48.
    Leavitt SB. Addiction treatment forums: methadone – drug interactions. 2009. www.atforum.com/SiteRoot/pages/rxmethadone/methadonedruginteractions.shtml. Accessed 2009.
  49. 49.
    Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain. 2003;105(3):499–506.PubMedCrossRefGoogle Scholar
  50. 50.
    Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very high dose methadone. Ann Intern Med. 2002;137:501–4.PubMedGoogle Scholar
  51. 51.
    Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet. 2000;356:2069–70.PubMedCrossRefGoogle Scholar
  52. 52.
    Ripamonti C, Conno FD, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol. 1998;9(1):79–83.PubMedCrossRefGoogle Scholar
  53. 53.
    Gazelle G, Fine PG. Methadone for the treatment of pain. J Palliat Med. 2003;6:621–2.CrossRefGoogle Scholar
  54. 54.
    Hanks G, Cherny N, Fallon M. Opioid analgesic therapy. In: Doyle D, Hanks G, Cherny N, et al (eds) Oxford Textbook of Palliative Medicine (3rd ed). Oxford University Press, 2004; pp. 318–21.PubMedGoogle Scholar
  55. 55.
    New Hampshire Hospice and Palliative Care Organization. 2010. http://www.nhhpco.org/opioid.htm. Accessed Apr 2010.
  56. 56.
    Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923.PubMedCrossRefGoogle Scholar
  57. 57.
    Raffa RB, Friderichs E, Reimann W. et al opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic. J Pharmacol Exp Ther. 1992;260:275–85.PubMedGoogle Scholar
  58. 58.
    Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J Pain. 2008;24(1):1–4.PubMedCrossRefGoogle Scholar
  59. 59.
    McCarberg B, Barkin R. Long-acting opioids for chronic pain; pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Kaplan R, Parris WC, Citron ML, et al. Comparison of controlled-release and immediate-release oxycodone tablets AVINZA and chronic noncancer pain – 263 inpatients with cancer pain. J Clin Oncol. 1998;16:3230–7.PubMedGoogle Scholar
  61. 61.
    American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. Glenview: American Pain Society; 2003.Google Scholar
  62. 62.
    Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009;9(6):468–79.PubMedCrossRefGoogle Scholar
  63. 63.
    Coluzzi PH, Shwartzberg L, Conroy Jr JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain. 2001;91:123–30.PubMedCrossRefGoogle Scholar
  64. 64.
    Mercadante S, Radbruch L, Popper L, Korsholm L, Davies A. Efficacy of intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain: open-label crossover trial. Eur J Pain. 2009;13:S198.CrossRefGoogle Scholar
  65. 65.
    Ripamonti C, Fagnoni E, Campa T, et al. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer. 2006;14:400–7.PubMedCrossRefGoogle Scholar
  66. 66.
    McCaffery M, Martin L, Ferrell BR. Analgesic administration via rectum or stoma. J ET Nurs. 1992;19:114–21.PubMedGoogle Scholar
  67. 67.
    DeConno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol. 1995;13(4):1004–8.Google Scholar
  68. 68.
    Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53(1):109–38.PubMedCrossRefGoogle Scholar
  69. 69.
    Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001;61(15):2289–307.PubMedCrossRefGoogle Scholar
  70. 70.
    Rathmell JP, Lair TR, Nauman B. The role of intrathecal drugs in the treatment of acute pain. Anesth Analg. 2005;101:S30–43.PubMedCrossRefGoogle Scholar
  71. 71.
    Gustafsson LL, Schildt B, Jacobsen K. Adverse effects of extradural and intrathecal opiates: report of a nation-wide survey in Sweden. Br J Anaesth. 1982;54:479–86.PubMedCrossRefGoogle Scholar
  72. 72.
    Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain. 1992;49:87–91.PubMedCrossRefGoogle Scholar
  73. 73.
    Brant JM. Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs. 2001;5:163–5.PubMedGoogle Scholar
  74. 74.
    Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract. 2010;10(2):85–93.PubMedCrossRefGoogle Scholar
  75. 75.
    Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.PubMedCrossRefGoogle Scholar
  76. 76.
    Yuan Y, Chen JY, Guo H, et al. Relief of abdominal pain by morphine without altering physical signs in acute appendicitis. Chin Med J (Engl). 2010;123(2):142–5.Google Scholar
  77. 77.
    Lvovschi V, Aubrun F, Bonnet P, et al. Intravenous morphine titration to treat severe pain in the ED. Am J Emerg Med. 2008;26:676–82.PubMedCrossRefGoogle Scholar
  78. 78.
    Valeberg BT, Rustoen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain. 2008;12(5):582–90.PubMedCrossRefGoogle Scholar
  79. 79.
    Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1):1–39.PubMedGoogle Scholar
  80. 80.
    Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am. 2007;91:199–211.PubMedCrossRefGoogle Scholar
  81. 81.
    Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008;9(6):724–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304–15.PubMedCrossRefGoogle Scholar
  83. 83.
    Ballantyne J. Opioid analgesia: perspective on right use and utility. Pain Physician. 2007;10:479–91.PubMedGoogle Scholar
  84. 84.
    Substance Abuse and Mental Health Services Administration. Results from the 2006 national survey on drug use and health. National findings. Office of Applied Studies, NSDUH Series: H-32, DHHS Publication No. SMA 07-4293. Rockville. 2007.Google Scholar
  85. 85.
    Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9(1):57–60.PubMedGoogle Scholar

Copyright information

© American Academy of Pain Medicine 2013

Authors and Affiliations

  1. 1.Algone Pain CenterSt. AugustineUSA

Personalised recommendations